

**Prof. Dr. rer. nat. et med. habil. Hartmut Kleinert**

\*11.03.1960

Professor of Molecular Pharmacology, W2  
Provisional Director of the Institute for Pharmacology  
Working Group Leader „Molecular Pharmacology/Immune Pharmacology“



Institute for Pharmacology  
University Medical Center of the Johannes Gutenberg University Mainz  
D-55131 Mainz, Obere Zahlbacher Str. 67, building 905  
Tel: +49-6131-17 9150  
[kleinert@uni-mainz.de](mailto:kleinert@uni-mainz.de)  
[www.unimedizin-mainz.de/1-med/patienten/mitarbeiter/portraits/marquardt.html](http://www.unimedizin-mainz.de/1-med/patienten/mitarbeiter/portraits/marquardt.html)

**Academia**

- |           |  |
|-----------|--|
| 1999      | Habilitation at the Institute for Pharmacology, Johannes Gutenberg University Mainz              |
| 1989      | Doctorate (Dr. rer. nat., „summa cum laude“), Department of Biochemistry, Ruhr-University Bochum |
| 1979-1986 | Studies in Biology/Chemistry (Diploma), Ruhr-University Bochum                                   |

**Career**

- |            |   |
|------------|---|
| since 2013 | Provisional Director, Institute for Pharmacology, Johannes Gutenberg University Mainz                   |
| 2008-2013  | Deputy Director, Institute for Pharmacology, Johannes Gutenberg University Mainz                        |
| since 2005 | W2-Professor of Molecular Pharmacology, Institute for Pharmacology, Johannes Gutenberg University Mainz |
| 1995-2005  | Academic Council/Supreme Council, Institute for Pharmacology, Johannes Gutenberg University Mainz       |
| 1993-1995  | Research Associate, Institute for Pharmacology, Johannes Gutenberg University Mainz                     |
| 1991-1993  | Research Associate, Department for Gastroenterology (Prof. Stremmel), University Clinic Düsseldorf      |
| 1986-1991  | Research Associate, Department for Biochemistry (Prof. Benecke), Ruhr-University Bochum                 |

**Awards**

- |           |   |
|-----------|---|
| 2000      | Schmiedeberg-Posterprize for Experimental Pharmacology        |
| 1999      | Boehringer-Ingelheim-Prize                                    |
| 1988-1989 | Graduate Fellowship of North Rhine-Westphalia                 |
| 1983-1986 | Scholarship holder of the German National Academic Foundation |

## Memberships

- German Society for Experimental and Clinical Pharmacology and Toxicology (DGPT)
- German University Association

## Selected Publications

Siuda, D., Wu, Z., Chen, Y., Guo, L., Linke, M., Zechner, U., Xia, N., Reifenberg, G., **Kleinert, H.**, Forstermann, U. et al. (2014) Social isolation-induced epigenetic changes in midbrain of adult mice. *Journal of physiology and pharmacology: an official journal of the Polish Physiological Society*, 65, 247-255.

Scherer, O., Steinmetz, H., Kaether, C., Weinigel, C., Barz, D., **Kleinert, H.**, Menche, D., Muller, R., Pergola, C. and Werz, O. (2014) Targeting V-ATPase in primary human monocytes by archazolid potently represses the classical secretion of cytokines due to accumulation at the endoplasmic reticulum. *Biochem Pharmacol*, 91, 490-500.

Henke, J., Erkel, G., Brochhausen, C., **Kleinert, H.**, Schwarting, A., Menke, J. and Pautz, A. (2014) The fungal lactone oxacyclododecindione is a potential new therapeutic substance in the treatment of lupus-associated kidney disease. *Kidney international*, 86, 780-789.

Xia, N., Strand, S., Schlüter, F., Siuda, D., Reifenberg, G., **Kleinert, H.**, Forstermann, U. and Li, H. (2013) Role of SIRT1 and FOXO factors in eNOS transcriptional activation by resveratrol. *Nitric Oxide*, 32, 29-35.

Reifenberg, K., Cheng, F., Twardowski, L., Kupper, I., Wiese, E., Bollmann, F., **Kleinert, H.**, Blessing, M., Lackner, K.J. and Torzewski, M. (2013) T Cell-Specific Overexpression of TGFss1 Fails to Influence Atherosclerosis in ApoE-Deficient Mice. *PLoS One*, 8, e81444.

Casper, I., Nowag, S., Koch, K., Hubrich, T., Bollmann, F., Henke, J., Schmitz, K., **Kleinert, H.** and Pautz, A. (2013) Post-transcriptional regulation of the human inducible nitric oxide synthase (iNOS) expression by the cytosolic poly(A)-binding protein (PABP). *Nitric Oxide*, 33C, 6-17.

Bollmann, F., Fechir, K., Nowag, S., Koch, K., Art, J., **Kleinert, H.** and Pautz, A. (2013) Human inducible nitric oxide synthase (iNOS) expression depends on chromosome region maintenance 1 (CRM1)- and eukaryotic translation initiation factor 4E (eIF4E)-mediated nucleocytoplasmic mRNA transport. *Nitric Oxide*, 30, 49-59.